Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 9/20 | 0.53 |
| ▸ | GABRG2 | P18507 | 9/20 | 0.53 |
| ▸ | GABRB3 | P28472 | 9/20 | 0.53 |
| ▸ | GABRA5 | P31644 | 9/20 | 0.53 |
| ▸ | GABRA3 | P34903 | 9/20 | 0.53 |
| ▸ | GABRA2 | P47869 | 9/20 | 0.53 |
| ▸ | GABRP | O00591 | 6/20 | 0.53 |
| ▸ | GABRD | O14764 | 6/20 | 0.53 |
| ▸ | GABRB1 | P18505 | 6/20 | 0.53 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.53 |
| ▸ | GABRA4 | P48169 | 6/20 | 0.53 |
| ▸ | GABRE | P78334 | 6/20 | 0.53 |
| ▸ | GABRA6 | Q16445 | 6/20 | 0.53 |
| ▸ | GABRG1 | Q8N1C3 | 6/20 | 0.53 |
| ▸ | GABRG3 | Q99928 | 6/20 | 0.53 |
| ▸ | GABRQ | Q9UN88 | 6/20 | 0.53 |
| ▸ | TOP2A | P11388 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29388457 | 0.82 | GABRA1 (0.59) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL3228276 | 0.82 | GABRA1 (0.59) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| Iodide SCHEMBL9958847 | 0.81 | GABRA1 (0.57) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL3233124 | 0.75 | GABRA1 (0.61) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL12240630 | 0.75 | GABRA1 (0.69) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL2358761 | 0.70 | CDK4 (0.56) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL5576840 | 0.69 | KDM4E (0.61) | TOP2A | |
| SCHEMBL3227604 | 0.69 | GABRA1 (0.59) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL4512002 | 0.68 | CDK4 (0.49) | GABRA1GABRG2GABRB3GABRA5GABRA3 | |
| SCHEMBL1173042 | 0.68 | ALDH1A1 (0.67) | GABRA1GABRG2GABRB3GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3862354-A1 | INDOLOPYRIDINES AS EG5 KINESIN MODULATORS | 4SC AG (DE) | 2021-08-11 | — | — | EP | disclosed |
| EP-2824105-B1 | Indolopyridines as Eg5 kinesin modulators | 4SC AG (DE) | 2021-03-31 | — | — | EP | disclosed |
| EP-2824105-A1 | Indolopyridines as Eg5 kinesin modulators | 4SC AG (DE) | 2015-01-14 | — | — | EP | disclosed |
| US-8530493-B2 | Indolopyridines as Eg5 kinesin modulators | 4SC AG (DE) | 2013-09-10 | — | — | US | disclosed |
| US-20110027226-A1 | INDOLOPYRIDINES AS INHIBITORS OF THE KINESIN SPINDLE PROTEIN (EG5) | 4SC AG (DE) | 2011-02-03 | — | — | US | disclosed |
| EP-2178875-A1 | INDOLOPYRIDINES AS INHIBITORS OF THE KINESIN SPINDLE PROTEIN (EG5 ) | 4SC AG (DE) | 2010-04-28 | — | — | EP | disclosed |
| US-20090246169-A1 | INDOLOPYRIDINES AS EG5 KINESIN MODULATORS | NYCOMED GMBH (DE) | 2009-10-01 | — | — | US | disclosed |
| US-20090233902-A1 | INDOLOPYRIDINES AS EG5 KINESIN MODULATORS | 4SC AG (DE) | 2009-09-17 | — | — | US | disclosed |
| WO-2009024190-A1 | INDOLOPYRIDINES AS INHIBITORS OF THE KINESIN SPINDLE PROTEIN (EG5 ) | 4SC AG (DE) | 2009-02-26 | — | — | WO | disclosed |
| EP-1996592-A1 | INDOLOPYRIDINES AS EG5 KINESIN MODULATORS | Nycomed GmbH (DE) | 2008-12-03 | — | — | EP | disclosed |
| EP-1994033-A1 | INDOLOPYRIDINES AS EG5 KINESIN MODULATORS | 4SC AG (DE) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007096395-A1 | INDOLOPYRIDINES AS EG5 KINESIN MODULATORS | 4SC AG (DE) | 2007-08-30 | — | — | WO | disclosed |
| WO-2007096393-A1 | INDOLOPYRIDINES AS EG5 KINESIN MODULATORS | 4SC AG (DE) | 2007-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110027226-A1 | INDOLOPYRIDINES AS INHIBITORS OF THE KINESIN SPINDLE PROTEIN (EG5) | KIF5A, KIF5C, KIF5B | GABRA1 4163/4885GABRG2 3872/4885GABRB3 3620/4885 |
| US-20090233902-A1 | INDOLOPYRIDINES AS EG5 KINESIN MODULATORS | KIF5A, KIF5C, KIF5B | GABRA1 4010/4885GABRG2 3511/4885GABRB3 3223/4885 |
| US-20090246169-A1 | INDOLOPYRIDINES AS EG5 KINESIN MODULATORS | KIF5A, KIF5C, KIF5B | GABRA1 4010/4885GABRG2 3511/4885GABRB3 3223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.